Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
暂无分享,去创建一个
S. Verstovsek | R. Hoffman | R. Paquette | M. Talpaz | J. Mascarenhas | T. Burn | Vikas Gupta | P. Coughlin | M. Savona | A. Turner | Jason Clark | E. Winton | L. Foltz | D. Hunter | A. Assad | Peter O'Neill | A. Turner